Abstract: The invention is comprised of a smoking composition of nicotine in the form of an inclusion complex located between crylisized polysaccharide and nicotine and a smoking material. The composition releases nicotine when exposed to elevated temperatures.

Abstract: This invention relates a method for topical treatment of glaucoma or ocular hypertension by administration of an effective intraocular pressure reducing amount of a prostaglandin derivative of PGA, PGB, PGE and PGF, in which the omega chain contains a ring structure. The invention further relates to compositions comprising said prostaglandin derivatives in an ophthalmologically compatible carrier.

Abstract: A compound of the formula Het--NR--SO.sub.2 --Ph.sup.2 --A--Ph.sup.1 (COOH)(OH) and tautomeric form, salts, solvates, C.sub.1-6 alkyl esters and pharmaceutical compositions of the compound. Ph.sup.1 and Ph.sup.2 are benzene rings with the proviso that carboxy and hydroxy are ortho to one another. Het includes an optionally substituted heterocyclic ring which includes conjugated double bonds and binds to nitrogen in NR. The compound is characterized in that A is a bridge which is stable against reduction because it is not azo, and in that R is hydrogen or lower alkyl.The invention also includes the preparation of the compound and its use as a drug, particularly for treating autoimmune diseases.

Abstract: The invention relates to the use of hGH, hGRF, hIGF-1, hIGF-2 or analogs of these or a mixture of two or more of these, alone or in conjunction with lactational enhancers for the treatment of human lactation failure. It also relates to the use of hGH, hGRF, hIGF-1, hIGF-2 or analogs of these or a mixture of two or more of these, alone or in conjunction with lactational enhancers for the manufacturing of a medicament for the treatment of human lactation failure, also a profphlactic treatment. Preferably human growth hormone is used. The invention also relates to a method for the treatment of human lactation failure as well as compositions and methods for their manufacturing.

Abstract: The present invention provides an O-Glycosylated Insulin-like Growth Factor 1 (IGF-1) analog of Insulin-like Growth Factor 1, a seventy amino acids single polypeptide chain which displays relatively high homology with proinsulin, essentially free from unglycosylated IGF-1.

Abstract: The method for demonstrating the presence of an activity of an enzyme by(a) incubating said enzyme with a fluorogenic substrate A which is converted by the enzyme to a product B differing from A in respect to its fluorescent properties, A and/or B carrying a chromophore which is a triplet sensitizer having a triplet energy level above the excitation energy level of a lanthanide ion selected from the group consisting of Eu.sup.3+, Tb.sup.3+, Dy.sup.3+ and Sm.sup.3+ and which is capable of chelating said lanthanide ion by means of an oxygen or nitrogen atom in said chromophore, and that B differs from A either by(i) carrying a different chromophore, or(ii) having a different chelating ability, and(b) measuring the change in fluorescence caused by said enzyme.

Abstract: A prefilled syringe including a vial containing a measured quantity of an injectable product is provided Adjacent an end the vial is a displaceable wall adapted to be urged by plunger means so as to expel the product from the vial through a needle. The syringe also includes a two part housing for the vial and the plunger. One of the housing parts includes a stop surface that cooperates with a pair of corresponding surfaces extending from an external surface of the plunger. The plunger stop surfaces are positioned on opposite sides of the housing part stop surface to limit the displacement of the plunger within the vial. The position of the stop surfaces on the plunger relative to the vial may be varied by rotating the threadably connected housing parts relative to each other. A click-stop mechanism provided with the housing parts permits the housing parts to be rotated relative to each other in predetermined increments. A graduated dosing ring may be rotatably mounted about the housing parts.

Abstract: A natural antioxidant for stabilizing polyunsaturated oils is disclosed. This oil-soluble antioxidant is prepared by dissolving ascorbic acid in a polar solvent, dissolving phospholipid in a non-polar solvent and then mixing the ascorbic acid solution with the phospholipid solution. After removing the solvent a product is formed which has anti-oxidant properties and is soluble in non-polar solvents.

Abstract: A method is provided for cleansing a protein from multivalent metal ions bound thereto, these ions being released from the protein by exchanging the ions with monovalent metal ions, whereafter the multivalent metal ions are removed. The release and removal of these ions is effected, in particular, by diafiltration or gel filtration processes.

Abstract: The invention is related to the field of treating gastric and duodenal disorders and more specifically to the use of certain 13,14-dihydro-prostaglandin E derivatives, especially of PGE.sub.2, which are modified to contain a ring structure in the omega chain. The invention relates also to pharmaceutical compositions containing an active amount of these derivatives.

Abstract: Intraocular implants having optical lenses that are light, non-toxic, biocompatible, nonleachable in the presence of eye fluids and absorb at least 90% of the ultraviolet light in the 300-380 nm wavelength range but are transparent to most of the visible radiation. The intraocular implants will have a haptic for fixation in the posterior or anterior chamber of the eye. The optical lens has uniformly dispersed therein an ultraviolet light absorbing amount of 2-(hydroxy-lower alkylphenyl) benzotriazole which may be halogen substituted in the 4, 5, 6 or 7 positions.

Abstract: A composition for the prevention of adhesions between body tissues after a surgical operation, containing dextran and hyaluronic acid. The composition further claims the use of said components for the preparation of such a composition as well as its use as an agent for the prevention of adhesions.

Abstract: The invention concerns an intravaginal device comprising a combination of 17.beta.-estradiol and a supporting matrix for treating hypoestrogenic women. The device releases continously 17.beta.-estradiol at a rate of about 0.5 to about 25 .mu.g/24 h. The invention also comprises a method of preparing the device and a method of treating hypoestrogenic women by using the device.

Abstract: A test strip having at least one patch thereon and intended for use in occlusive epicutaneous testing in order to detect contact allergy to formaldehyde. The characteristic feature is that on at least one of the patches the test substance is a reversible N-formaldehyde derivative of succinimide which is formulated in a dry buffered vehicle.

Abstract: An intraocular lens having a substantially circular optical portion and two separate fixation arms each having an inner end and an outer free end. The fixation arms are each attached to the optical portion via a short connecting member which extends substantially radially from the optical portion circumference and is of approximately the same thickness and flexibility as the fixation arm to which it is attached.

Abstract: The present invention concerns a transdermal system with a reservoir layer comprising an active substance, at least part of which is in the form of an inclusion complex formed between a cyclo compound and the active substance. The release rate from the system is controlled by the dissociation of the complex.

Abstract: 11-epi PGF.sub.2 alpha esters are employed in treating glaucoma or ocular hypertension.

Abstract: An apparatus for facilitating the release of an ingredient of a plastic or elastic sample of a pharmaceutical or confectionery material while the sample is in contact with a liquid medium which includes a base, a fixed lower jaw, a movable upper jaw and a member for moving the upper jaw toward and away from the lower jaw, a support for mounting and supporting a sample in the space between the upper surface of the lower jaw and the lower surface of the upper jaw, and a container surrounding both the jaws and sample so as to confine a liquid medium to the area surrounding the sample.

Abstract: A method for the topical treatment of glaucoma or ocular hypertension which comprises contacting the surface of the eye with a composition consisting essentially of an effective intraocular pressure reducing amount of a mixture of (a) an adrenergic agonist selected from the group consisting of epinephrine, dipivalylepinephrine, norepinephrine, phenylephrine, clonidine, isoproterenol, salbutamol, metaproterenol and terbutaline, and (b) a phosphodiesterase inhibitor selected from the group consisting of isobutylmethylxanthine, theophyllamine, Rolipram and RO-2017624, in an ophthalmically compatible carrier.